reviews of noom glp-1 Launches Microdosing for Longevity Noom Enters Longevity Market with

You know tirzepatide is the right choice for your weight loss goals

However, the 12mg maintenance dose still requires multiple draws or a 1mL+ syringe

Studies have shown that GLP-1 receptor agonists provide better glycemic control and lower the risks of hypoglycemia compared to other anti-diabetes medications

The Institute for Clinical and Economic Review deemed GLP-1s lacking in cost effectiveness for obesity management in 2022

While the adjustment period can be significant, many bariatric patients find that these habits gradually become part of their everyday routine

Given the FDA's April 2026 proposal with a comment period closing June 29, 2026, this a real question for anyone starting a multi-month compounded GLP-1 program right now